-

06:38:06 PM

VSTM Stock News

VSTM - Verastem Inc

01/24/23 5:46 PM

Nasdaq : VSTM

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

The initial tranche, consisting of 1.2 million shares of Preferred Stock for gross proceeds of approximately $30 million, representing a purchase price per common share equal to $0.5901, is anticipated to close on January 27, 2023, subject to the satisfaction of customary closing conditions. The second tranche, consisting of 0.9 million shares of Preferred...

RHEA-AI

neutral

01/24/23 5:45 PM

Nasdaq : VSTM

clinical trial

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announces positive interim data from Part A of the ongoing RAMP 201 international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with...

RHEA-AI

positive

01/18/23 4:05 PM

Nasdaq : VSTM

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dan Calkins Investor Relations +1 781-469-1694 dcalkins@verastem.com. Nate LiaBraaten +1 212-600-1902 nate@argotpartners.com. Lisa Buffington VP, Corporate Communications +1 781-292-4205 lbuffington@verastem.com.

RHEA-AI

very positive

12/15/22 4:30 PM

Nasdaq : VSTM

management

Verastem Oncology Appoints Rob Gagnon to Board of Directors

Mr. Gagnon is the Chief Financial Officer and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund and the former Chief Business Officer and Chief Financial Officer at Verastem Oncology. “I am committed to Verastem’ s mission to deliver a new solution to patients with low-grade serous ovarian cancer and advancing the...

RHEA-AI

neutral

11/03/22 4:05 PM

Nasdaq : VSTM

earnings

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress. Verastem recently conducted a second planned interim analysis of the ongoing RAMP 201 trial among patients with recurrent LGSOC.

RHEA-AI

neutral

10/20/22 7:00 AM

Nasdaq : VSTM

management

Verastem Oncology Appoints Anil Kapur to Board of Directors

Mr. Kapur is the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation. Previously, Mr. Kapur was Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, which was acquired by Shire PLC in 2016. Mr. Kapur holds a BE from Birla Institute of Technology in India, an MS in Industrial...

RHEA-AI

very positive

10/07/22 4:05 PM

Nasdaq : VSTM

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 22,500 shares of its common stock and the grant of 15,000 restricted stock units to one new employee. The stock options have an exercise price equal to $0.87 per share, the closing price of...

RHEA-AI

very positive

10/04/22 7:00 AM

Nasdaq : VSTM

clinical trial

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

Verastem recently conducted a second planned interim analysis of the ongoing RAMP 201 trial among patients with recurrent LGSOC. Based on the results, including independently confirmed responses and no new safety signals, the Company is planning to meet with the U.S. Food and Drug Administration in the fourth quarter to review the data set, discuss the go...

RHEA-AI

positive

08/08/22 7:00 AM

Nasdaq : VSTM

earnings

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress. “In the second quarter, we announced findings from the interim analysis of our registration-directed RAMP 201 trial in low-grade serous...

RHEA-AI

neutral

07/07/22 7:00 AM

Nasdaq : VSTM

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The stock options have an exercise price equal to $1.13 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 1, 2022. Ajay Munshi VP, Corporate Development +1 781-469-1579 amunshi@verastem.com. Nate LiaBraaten +1 212-600-1902 nate@argotpartners.com.

RHEA-AI

very positive

VSTM Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.verastem.com
CeoBrian Stuglik
Security nameVerastem Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees48
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address117 Kendrick St Ste 500
StateMassachusetts
CityNeedham
Zip02494-2730
CountryUS
Phone17812924200

About Verastem Inc

Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition.